Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 12:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Gralise® Clear all

Conditions: Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis, Pelvic Pain
Interventions: Gralise; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alcohol Dependence
Interventions: Prometa Treatment Program; Drug
Lead sponsor: Institute of Addiction Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Gabapentin 800 mg Tablets, single dose, NEURONTIN® 800 mg Tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Gabapentin 800 mg Tablets, single dose, NEURONTIN® 800 mg Tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Abuse Potential
Interventions: gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo; Drug
Lead sponsor: Viatris Specialty LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions: donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Cleveland, Ohio

Conditions: Healthy
Interventions: Gabapentin tablets 800 mg; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Pain
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Post-laminectomy Pain Syndrome
Interventions: Gralise®, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy
Interventions: Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules); Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Gabapentin 400 mg capsules, NEURONTIN® 400 mg capsules; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Restless Leg Syndrome
Interventions: Gabapentin immediate release, Gabapentin enacarbil extended release; Drug
Lead sponsor: Theresa Zesiewicz, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy Non-dependent, Recreational Sedative Users
Interventions: Alprazolam (Xanax), Placebo, Gabapentin (Neurontin® (Registered Trademark)); Drug
Lead sponsor: Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Anxiety Disorder, Mood Disorder, Psychotic Disorder
Interventions: Lamotrigine (Lamictal® (Registered Trademark), Gabapentin (Neurontin® (Registered Trademark)); Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules); Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Gabapentin 400 mg capsules, NEURONTIN® 400 mg capsules, Gabapentin 400 mg capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 1998
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions: Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 7
States / cities: Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more

Conditions: Healthy
Interventions: Gabapentin tablets 800 mg; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Abuse Potential
Interventions: gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg, diazepam 20 mg, placebo; Drug · Other
Lead sponsor: Viatris Specialty LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Efficacy of Gralise® for Chronic Pelvic Pain

Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence

A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions

A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions

Gabapentin for Pain Management During Dilation and Evacuation

GRASSP: Gralise® for Spine Surgery Pain

A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience

New Drugs in the Treatment of Mood Disorders

A Limited Food Effect Study of Gabapentin 800 mg Tablets

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions

Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience